Rebecca R. Shoemaker

Pain Medicine
860 Omni Blvd Ste 115
Newport News, VA 23606

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.

The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.

Journal: Antimicrobial agents and chemotherapy
Published: October 07, 2025

Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.

Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.

Journal: The Journal of clinical investigation
Published: July 22, 2025

Identification of initial sites of SIV rebound after treatment cessation.

Identification of initial sites of SIV rebound after treatment cessation.

Journal: Research square
Published: July 17, 2025

Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.

Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.

Journal: Nature microbiology
Published: July 07, 2025

Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques.

Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques.

Journal: bioRxiv : the preprint server for biology
Published: April 08, 2025

Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.

Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.

Journal: Frontiers in microbiology
Published: March 14, 2025

Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.

Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: January 22, 2025

Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.

Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.

Journal: PLoS pathogens
Published: May 15, 2024

Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir.

Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir.

Journal: PLoS pathogens
Published: December 31, 2023

Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.

Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.

Journal: Science immunology
Published: June 17, 2022

Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy.

Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy.

Journal: Science immunology
Published: January 12, 2021

Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.

Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.

Journal: PLoS pathogens
Published: January 05, 2021
Showing 1-12 of 26

Last Updated: 09/26/2026